Protara Therapeutics, Inc.
TARA
$3.97
-$0.07-1.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 21.93% | 23.73% | 21.34% | 36.08% | 21.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.98% | 33.31% | 19.71% | 55.58% | 19.18% |
| Operating Income | -38.98% | -33.31% | -19.71% | -55.58% | -19.18% |
| Income Before Tax | -49.25% | -35.54% | -18.17% | -57.26% | -7.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.25% | -35.54% | -18.17% | -57.26% | -7.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.25% | -35.54% | -18.17% | -57.26% | -7.38% |
| EBIT | -38.98% | -33.31% | -19.71% | -55.58% | -19.18% |
| EBITDA | -39.16% | -33.42% | -19.81% | -55.87% | -19.32% |
| EPS Basic | -5.57% | 22.19% | 37.58% | 21.00% | 69.87% |
| Normalized Basic EPS | -5.63% | 22.19% | 37.58% | 21.00% | 69.88% |
| EPS Diluted | -5.57% | 22.19% | 37.58% | 21.00% | 69.87% |
| Normalized Diluted EPS | -5.63% | 22.19% | 37.58% | 21.00% | 69.88% |
| Average Basic Shares Outstanding | 41.35% | 74.18% | 89.31% | 99.08% | 256.43% |
| Average Diluted Shares Outstanding | 41.35% | 74.18% | 89.31% | 99.08% | 256.43% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |